New Study Projects Future of Approvals, Patients Treated, Costs, and Gaps in Treatment Options Boston, May 14, 2025—New research in Journal of Managed Care + Specialty Pharmacy (JMCP) provides insights into the future … Read More
Journal of Managed Care + Specialty Pharmacy: 10-year projection of pediatric onset rare disease therapy approvals, treated patients, and list price revenues
New research in Journal of Managed Care + Specialty Pharmacy (JMCP) provides insights into the future landscape of treatments for rare diseases that present in childhood, offering a balanced picture … Read More
NEWDIGS explores System Dynamics Modeling to address barriers to access of effective therapies
System barriers to the appropriate, timely, and equitable use of biomedical innovations have led to slow and inconsistent adoption, limiting their full potential impact on patient outcomes. For 16 years … Read More
Nature Reviews Drug Discovery: Clinical development success rates for durable cell and gene therapies
Our article compares the clinical development success rates of durable cell and gene therapies (dCGTs) from 1988 to 2023 with BIO and IQVIA’s published benchmarks for all therapeutic modalities. As … Read More
Nature Reviews Drug Discovery: Clinical development success rates for durable cell and gene therapies
Our article compares the clinical development success rates of durable cell and gene therapies (dCGTs) from 1988 to 2023 with BIO and IQVIA’s published benchmarks for all therapeutic modalities. As … Read More
Health Affairs Forefront: Bringing Systems Thinking to Drug Value Assessment
Drug value assessments generally fail to account for the complexities of health care systems and thus can misinform price negotiations and lead to overly restrictive access policies. Our [new article … Read More
Health Affairs Forefront: Bringing Systems Thinking to Drug Value Assessment
Drug value assessments generally fail to account for the complexities of health care systems and thus can misinform price negotiations and lead to overly restrictive access policies. Our [new article … Read More
Implementation Brief: Implementing an innovative contract
The contract is signed—now what? Next, stakeholders must prepare to implement the innovative contract. This brief offers a checklist of potential considerations for executing the agreement, including aligning stakeholders and … Read More
Implementation Brief: Designing an innovative contract
Once the decision has been made to move forward with an innovative contract for a specific medical treatment, the details of a contract must be designed. This brief offers a … Read More
Implementation Brief: Is innovative contracting right for you?
Innovative contracts can offer significant benefits for stakeholders delivering novel drugs and medical products to patients — but they require resources to design and implement. This Implementation Brief outlines key … Read More